ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE Drug Patent Profile

Which patents cover Ondansetron Hydrochloride Preservative Free, and when can generic versions of Ondansetron Hydrochloride Preservative Free launch?

Ondansetron Hydrochloride Preservative Free is a drug marketed by Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Hospira, Onesource Specialty, Sandoz, Sun Pharm Inds Ltd, Taro Pharms Ireland, Teva, and Wockhardt Bio Ag. and is included in twenty NDAs.

The generic ingredient in ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE is ondansetron hydrochloride. There are twenty-eight drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the ondansetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ondansetron Hydrochloride Preservative Free

A generic version of ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE was approved as ondansetron hydrochloride by FRESENIUS KABI USA on December 26^th, 2006.

Summary for ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

US Patents:	0
Applicants:	16
NDAs:	20
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	13
Patent Applications:	2,493
DailyMed Link:	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE at DailyMed

Recent Clinical Trials for ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of North Carolina, Chapel Hill	PHASE4
Wayne State University	PHASE1
University of Pennsylvania	Phase 3

See all ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE clinical trials

Pharmacology for ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

US Patents and Regulatory Information for ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	206845-001	Mar 10, 2016		DISCN	No	No
Taro Pharms Ireland	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	078014-001	Mar 21, 2008		DISCN	No	No
Eugia Pharma	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	202600-001	Dec 21, 2012		DISCN	No	No

Market Dynamics and Financial Trajectory for ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

Last updated: March 22, 2026

What is the current market scope for preservative-free ondansetron hydrochloride?

Preservative-free ondansetron hydrochloride (PfO), mainly used as an antiemetic, addresses the needs of patients with sensitivities to preservatives used in formulations. The global ondansetron market projected to reach USD 1.3 billion by 2028, with an expected compound annual growth rate (CAGR) of approximately 4% (MarketsandMarkets, 2022).

PfO formulations are a subset within this market segment, earning interest due to increased demand from oncology, chemotherapy, post-operative nausea, and pediatric care sectors. The emphasis on preservative-free drugs grows in hospitals and outpatient settings to reduce adverse reactions and improve patient safety.

How is the market for preservative-free formulations evolving?

The shift towards preservative-free drugs results from regulatory, clinical, and patient safety considerations. Regulatory agencies such as the FDA and EMA encourage preservative-free options, reducing preservative-related adverse effects—especially with repeated doses or for vulnerable populations.

Market drivers include:

• Growing oncology and chemotherapy patient populations
• Increased awareness of preservative-related allergenic reactions
• Favorable policy environment for preservative-free formulations
• Technological advancements in drug delivery systems (e.g., pre-filled syringes, single-dose vials)

Market restraints involve:

• Higher manufacturing costs for preservative-free formulations
• Limited availability of stable preservatives-free formulations
• Challenges in maintaining drug stability and shelf-life

What is the competitive landscape?

Key players include Pfizer, Mylan, Teva, and Sagent Pharmaceuticals. These companies are investing in R&D to develop and commercialize preservative-free formulations, with Pfizer already marketing preservative-free formulations of ondansetron for injectable use.

Pfizer’s product, Zofran Pf (preservative-free), captures a significant share, driven by its established market presence and distribution channels. Biosimilar entrants and private-label manufacturers are exploring preservative-free options to compete on price and safety profiles.

Market share within the preservative-free segment remains small but expanding, representing approximately 10-15% of total ondansetron sales in developed regions.

What is the financial outlook?

Projected revenue growth for preservative-free ondansetron formulations is approximately 6-8% annually in the next five years, driven by regional policy shifts and healthcare provider preferences. Industry estimates suggest that global preservative-free ondansetron segment revenues could reach USD 250-300 million by 2028, up from an estimated USD 150 million in 2022.

Pricing trend: A premium of 10-15% over preserved formulations exists, reflecting manufacturing complexity and safety benefits. This premium sustains revenue margins despite higher production costs.

Cost considerations: Scaling manufacturing and adopting advanced stability techniques are critical for improving margins. R&D investments targeting long-term stability and shelf-life extension are ongoing, aiming for cost reduction.

What are the key regulatory and clinical challenges?

• Need for rigorous stability data for preservative-free formulations
• Stringent approval processes requiring comprehensive safety profiles
• Variability in regional regulatory requirements complicates global commercialization

What are the future opportunities and risks?

Opportunities:

• Expansion into pediatric and sensitive patient groups with high safety demands
• Adoption in emerging markets with evolving healthcare infrastructure
• Development of consumer-friendly formats (e.g., oral films, pre-filled syringes)

Risks:

• Technological challenges in maintaining product stability
• Limited reimbursement and pricing pressures
• Competitive pressure from new molecular entities or alternative antiemetics

Summary table: Key market statistics (2022–2028)

Metric	2022	2028 (Projected)	CAGR
Global ondansetron market revenue	USD 1.0 billion	USD 1.3 billion	4%
Preservative-free ondansetron share	~15%	~25%	8%
Preservative-free segment revenue	USD 150 million	USD 250-300 million	6-8%
Pricing premium over preserved formulations	10-15%	Same	N/A

Key takeaways

• The preservative-free ondansetron market is expanding due to safety and regulatory support.
• Revenue is projected to grow at about 6-8% annually, reaching USD 250-300 million by 2028.
• Manufacturing cost and stability challenges persist but are being addressed through technological innovation.
• Competitive landscape remains concentrated, with limited market share for PfO but increasing adoption across regions.
• Regulatory complexity and reimbursement dynamics influence commercialization strategies.

FAQs

1. What factors influence the pricing of preservative-free ondansetron?
Pricing is affected by manufacturing complexity, formulation stability, regional regulatory requirements, and premium positioning for safety.

2. Are there significant regional differences in the adoption of preservative-free ondansetron?
Yes. Developed markets like North America and Europe have higher adoption rates due to stricter regulations and safety preferences. Emerging markets are gradually adopting such formulations as healthcare standards evolve.

3. What are the main technological innovations enabling preservative-free formulations?
Advances include stable excipient systems, advanced lyophilization techniques, and pre-filled delivery devices that enhance shelf life and ease of use.

4. Will biosimilars affect the preservative-free ondansetron market?
Biosimilars may influence market dynamics by offering lower-cost alternatives, but preservative-free formulations are more driven by safety considerations than biosimilar competition.

5. How do regulatory agencies impact the market trajectory?
Regulatory agencies' encouragement of preservative-free options and strict safety standards propel development and approval but can also introduce delays and increased costs for market entry.

---

References

[1] MarketsandMarkets. (2022). Anti-emetics Market - Global Forecast to 2028. Retrieved from https://www.marketsandmarkets.com/

[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Preservative-Free Injectable Drugs.

[3] European Medicines Agency. (2020). Policy on the development of preservative-free formulations.